Drop the evaluation workbook (.xlsx) to load it ⇩
Scientific Due Diligence

Sample dossier

CategoryInflammatory bowel disease
ModalityGut-selective siRNA
StagePreclinical · seed
ILLUSTRATIVE SAMPLEsynthetic asset
Asset
Overall
--
evidence strength
View
Where it stands today
Realistic aim for this stage
meets the aim
evidence pending
band = how much each factor weighs in the score
LimitedModerateStrongRobust
The people behind the company
In a live evaluation, the team and advisors are named here and assessed on the Execution axes above. In this illustrative sample the company and its people are synthetic, so no names are shown.
Every company Zetesis evaluates is scored on the same twelve evidence axes, in the same places, so any two companies compare on one frame. The dashed ring is the realistic aim for a seed / IND-enabling company, not a perfect score, so the human-evidence axis cannot be green yet. This is an illustrative sketch; the full evaluation comes from the Zetesis engine. Hover a weight band to see how much each factor counts at this stage.
Terms. IBD inflammatory bowel disease · siRNA small interfering RNA · IND Investigational New Drug · GMP Good Manufacturing Practice · FTO freedom-to-operate · IP intellectual property · CMC chemistry, manufacturing and controls